Abstract
Introduction Nowadays, chronic kidney disease (CKD) has been recognized as a major public health burden [1, 2] . In sub-Saharan Africa (SSA), CKD increased healthcare costs and is emerging as one of the major health threats contributing every year to millions of premature deaths. It affects young adults in their productive years, particularly in high risk groups of people with hypertension, diabetes, obesity, sickle cell disease or HIV infection [3] [4] [5] [6] [7] [8] . Early detection and timely intervention of CKD can prevent or delay these adverse outcomes [9, 10] . Thus, the increased prevalence of CKD emphasizes the need to establish appropriate and well validated methods to assess renal function. Proteinuria and glomerular filtration rate (GFR) are generally considered as the best indicators of kidney function [11] . The ideal method to evaluate GFR is by measuring clearance of an exogenous marker, such as inulin or iohexol, but this is costly and time-consuming [12, 13] . Because measuring GFR is relatively cumbersome, more simple biologic variables have been proposed based on serum creatinine (SCr) and demographic factors such as age, body size and sex [14, 15] . Available guidelines recommend the use of creatininebased equations, such as modification of diet in renal disease (MDRD) [15, 16] and CKD epidemiology collaboration (CKD-EPI), to estimate GFR [17] . To recognize CKD early and to properly manage kidney disease, the 2012 Kidney Disease Improving Global Outcomes (KDIGO) recommend using SCr and/or cystatin C-based equations to estimate GFR [18] . Recent studies have shown that estimated GFR using serum cystatin C (eGFR SCys) is not more precise than estimated GFR using SCr (eGFR SCr), whereas estimated GFR based on both markers (eGFRSCrCys) is more precise than eGFR based on either marker alone [19] [20] [21] . The limitation is linked to the fact that SCr concentration is dependent not only on GFR but also on muscular mass. Given the strong link to muscular mass, SCr concentration and creatinine excretion will vary with socioeconomic status, physical activity, nutrition, gender, age and ethnicity, independently of any GFR changes [22, 23] . For this reason, creatinine-based equations have been developed, including these last three variables to estimate GFR [14, 15, 21] . SCr concentration will also differ between ethnicities for the same GFR level because it is suspected that African people proportionally have a larger muscular mass than Caucasian or Asian populations [24] [25] [26] . Furthermore, some authors suggested that tubular secretion of creatinine could be different according to ethnicity [23, 27] , but this is still controversial [28] . Hence, MDRD and CKD-EPI-based equations proposed to use a correction factor for black Americans. Non critical application of these equations in SSA individuals appears questionable and highlights the need for their validation. Several studies have questioned the application of this ethnic factor to black Africans, particularly South-Africans, Ghanaians and Ivoirians [26, [28] [29] [30] . However, to date, there is no data showing the comparison of equations using creatinine alone or combined with cystatin C (with or without ethnic factor) with mGFR in the Central Africa population. Therefore, we assessed the performance of MDRD and different CKD-EPI equations in Congolese adults.
Methods

Study design and population
This current cross-sectional study is the fourth part of a larger ongoing epidemiological survey on CKD and associated risk factors termed ''Prévalence, détection précoce et prévention des maladies rénales chroniques et facteurs de risque associés (PDMRA) en République Démocra-tique du Congo", carried out between June 2015 and April 2016, in the general population of Kinshasa, capital of the Democratic Republic of the Congo (DRC).
All participants were visited twice at home by trained research personnel, who recorded information on demographics, diet, smoking, alcohol consumption, and use of indigenous herbal remedies. Data about family relatives of first degree and medical history for kidney disease, hypertension, diabetes and current treatment were also recorded. Body weight, height and abdominal circumference were measured.
The healthy persons were recruited from the general population as mentioned above. Before inclusion in the study for measurement of GFR by plasma clearance of iohexol, these subjects were screened for the absence of acute and chronic pathologies including hypertension, diabetes mellitus, obesity, cardiovascular diseases, renal dysfunction (eGFR CKD-EPI SCr < 60 or > 130 mL/min/1.73m 2 ), and urinary abnormalities (proteinuria, hematuria or leucocyturia) by urine dipstick ("Combur10 Test", Roche Diagnostics, Mannheim, Germany) on the morning urine. Participants were asked to avoid medications that affect GFR (e.g. antiinflammatory agents, diuretics, renin-angiotensin blocking agents) and those that can interfere with creatinine secretion (e.g. cimetidine or trimetroprim). Briefly, medication was not allowed except for contraceptives in the female participants.
The study protocol was approved by the Ethics Committee of the Public Health School of the University of Kinshasa (N˚ESP/CE/029/2015) and by the Institutional Review Boards at each site. Written informed consent was obtained from all participants, and all participants with abnormal findings received counseling, and educational pamphlets.
GFR measurement and estimation
GFR was measured using iohexol plasma clearance (Omnipaque, 240 mg I/mL, GE Healthcare, Belgium) as the method of reference once in every patient [12, 13, 31] . After verification of the participant's identity, a rest of 5 minutes was observed. The syringe with iohexol was weighed before and after the injection to an accuracy of 0.01 g. In the morning, a catheter was placed in a large vein of the forearm, and 5 mL of blood was taken at time 0 for the determination of both SCr and cystatin C. By the same vein, 5 ml of iohexol was injected before removing the catheter and the empty syringe was weighed. Then 4 blood samples were drawn from a different intravenous access (usually from the contralateral arm) at 120, 180, 240 and 300 minutes after the injection of iohexol [29] . The blood sample was allowed to stand for 30-60 minutes before being centrifuged. After centrifugation, samples were stored at -80˚C. Then, samples were shipped for iohexol measurement at the University laboratory of Liège, Belgium and then measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS), as previously described [32] . To assure the quality of iohexol measurements, the laboratory is accredited for the ISO 15189 Standard and also participates in the interlaboratory quality test for iohexol performed by Equalis AB, Uppsala, Sweden. The measured GFR (mGFR) was then calculated using the slope-intercept method, corrected with the Brochner-Mortensen equation [12] . In our hands, the intra-individual coefficient of variation for iohexol plasma clearance was 4.5% [12] . The results were normalized by body surface area (BSA) using the Gehan and Georges [33] ) was also estimated by using different equations as described in Table 1 . SCr levels were determined in the same laboratory by using an enzymatic method with an IDMS-traceable calibrator using the Roche Cobas (Roche Diagnostics, Mannheim, Germany). Serum Cystatin C levels were measured by the latex immunoturbidimetric method using Roche Cobas (Roche Diagnostics, Mannheim, Germany Mannheim, Germany) and standardized to ERM-DA 471/IFCC [34] .
Statistical analysis
All analyses and calculations were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). Data were expressed as mean ± standard deviation. The comparison of the mean of two or more groups was made using Student-t-test and ANOVA, respectively. We assessed the performance of the MDRD and CKD-EPI eGFRs with and without ethnic factors using the following statistical tools. Lin's Concordance Correlation Coefficient (CCC) evaluated the degree to which pairs of observations fall on the 45˚line through the origin. It's a measure of both correlation and agreement. Spearman correlation coefficients were added in the S1 File. Then, bias (the difference between eGFR-mGFR, systematic error) and relative bias were calculated. Precision was evaluated by the standard deviation of the bias (random error) and root-meansquare error (RMSE) (the square root of the mean squared differences eGFR-mGFR). Moreover, we considered the accuracy within 30% and 10%, i.e. the percentage of estimates falling within ±30% (P30) or ±10% (P10) of measured GFR [35, 36] . The difference in P30 accuracy between eGFRs was tested with the exact McNemar test. In S2 and S3 Files, sub-analyses according to gender and GFR tertiles were done. eGFR determined by each equation was finally compared with mGFR using the Bland-Altman analysis. The threshold of statistical significance was set at α = 0.05. SCr and CKD-EPI SCr without ethnic factor (CKD-EPI SCr nef), respectively ( Table 2) . Results of Lin's CCC showed a better result for equation without the ethnic factor compared to equation including the ethnic factor but the improvement was not statistically different. Bias of eGFRs without ethnic factor were not statistically different from equality, except for the MDRD equation which underestimated mGFR. At the opposite, a significant positive bias (eGFR overestimating mGFR) was observed for all equations with the ethnic correction.
Results
General characteristics of study population
Performance of equations
We compared P30 and P10 in a head-to-head analysis by exact McNemar tests (Table 4) . MDRD nef had a better P30 and P10 than CKD-EPI SCr (p = 0.0169 and p = 0.0091, respectively) but a lower P10 than CKD-EPI SCrCys nef (p = 0.0385). CKD-EPI SCr nef had a better P10 than CKD-EPI SCr and MDRD (p<0.0001 and p = 0.009, respectively) but a lower P30 than CKD-EPI SCys and CKD-EPI ScrCys (p = 0.0352 p = 0.002, respectively). MDRD had a better P10 than CKD-EPI SCr (p = 0.0106) but a lower P30 than CKD-EPI SCrCys (p = 0.0156) and a lower P30 and P10 than CKD-EPI SCys and CKD-EPI ScrCys nef (p = 0.0127, p = 0.0226 and p = 0.0005 and p = 0.0002, respectively). CKD-EPI SCr had a lower P30 and P10 than CKD-EPI SCrCys (p = 0.0002 and p = 0.0004, respectively) and a lower P30 and P10 than CKD-EPI SCys and CKD-EPI ScrCys nef (p = 0.0002, p<0.0001 and p<0.0001 and p<0.0001, respectively). Finally, CKD-EPI SCrCys nef had a better P30 (p = 0.0039) than CKD-EPI SCrCys. Sub-analyses of the performances of eGFR according to gender, GFR tertiles, and age were shown in S2, S3 and S4 Files, respectively. 
Discussion
In the present study, we compared several estimating GFR equations to mGFR obtained with iohexol plasma clearance. Two main messages could be drawn from our analysis. First, bias and accuracy of equations without ethnic factors were better than corresponding equations with the ethnic factors. Second, accuracy of CKD-EPI equations integrating cystatin C was globally slightly better than equations-based on SCr sole. We confirmed the inadequacy of African-American (AA) ethnic factors for the estimation of GFR of healthy adults in Africa and, for the first time, in Central Africa. Some authors have already criticized the AA factors both in MDRD and CKD-EPI equation. Indeed, it seems that these factors were too high, especially when applied to subjects with GFR above 60 mL/min/ 1.73m 2 [28, 29, 37] . Indeed, this AA ethnic factor was determined from AA subjects, who, for the vast majority, came from the African American Study of Hypertension and Kidney Disease (AASK) and had a GFR below 60 mL/min/1.73m 2 [38] . Moreover, differences could also occur between AA and populations living in Africa. Indeed, authors have shown that, at the same level of GFR, serum creatinine was higher in AA subjects compared to their Caucasian counterparts [39] . These differences were also observed in the African subject living in Europe, but too a much lesser extent. Comparing to a white European population, Flamant et al yielded that creatinine excretion and secretion rate were only slightly higher in African Europeans [28] . The ethnic factor applied to European African, including CKD patients, was thus much lower than the factor proposed originally for the AA. The relationship between SCr and GFR could however be still different in black Africans who live in a difficult socio-economic environment and not favorable to a food intake rich in creatinine-producing animal proteins. Indeed, Van Deventer et al have also shown that the AA ethnic factor lead to a strong overestimation of mGFR [30] in a black South-African population, including CKD patients [39] . Similar observations were also available in West-Africa (healthy people) [26, 29] (Côte d'Ivoire and Ghana). In these studies, as in ours, the performance of equations tended to be better when the AA factor was not applied, including for the CKD-EPI equation combining SCr and cystatin C. Using the AA factor also lead to very unexpected results regarding the bias of equations. Both the MDRD and CKD-EPI SCr overestimated mGFR (positive bias) when the ethnic factor was used in our healthy population. Without the ethnic factor, the bias of CKD-EPI SCr was not different and actually close to zero and the bias of MDRD became negative. These two results were totally expected in such a healthy population [17, 40] .
Again, the more plausible explanations for such errors in applying the AA ethnic factor is probably the difference in muscular mass and diet (protein-rich or not) between AA and black populations living in Africa. BMI are only indirect parameters to assess muscular mass, but compared to Congolese population in the current study who had an average BMI of 23.5±3.4 kg/m2, the mean BMI observed in the AASK study cohort was much higher at 30.7 kg/m 2 [38] . We also found that the CKD-EPI SCys equation performed better than both the MDRD and CKD-EPI SCr equation. Cystatin C is presented as a better marker of kidney function, especially because its concentration is less influenced by muscular mass or diet than SCr [41] . The best illustration is the absence of any ethnic factor in the CKD-EPI SCys equation. This observation may be of great benefit to populations living in Africa where many are from a low socioeconomic group and suffer from diseases such HIV [39] . However, in DRC, as in almost all the countries of SSA, the dosage of cystatin C is not in common use and more expensive than SCr. The slightly better performance of cystatin C suggested by our results are actually probably not enough to compensate the additional cost of this marker in daily practice.
The main conclusions of the current analysis, i.e. the better results without the ethnic factor and the slightly better performance of cystatin C-based equations remain valid in sub-analyses according to gender and GFR tertiles.
Our study has several limitations. First, it concerned only black, healthy, and Congolese subjects living in an urban environment (Kinshasa). The results need to be confirmed in CKD patients, Caucasians living in Central Africa and in rural areas. In addition, black Congolese living in developed countries, which have changed the diet and the lifestyle, was not integrated. Second, the relatively small size of our sample does not allow us to generalize our findings to the entire Congolese population. In the same view, sub-analyses results according to gender, GFR tertiles and age must be interpreted with caution because of the low sample size. Third, the results of accuracy comparisons must also be analyzed carefully because of the relatively small size of our sample and the high GFR ranges.
In conclusion, we confirmed that AA ethnic factors applied to MDRD, CKD-EPI SCr and CKD-EPI SCrCys are not suitable for a healthy population in Central Africa. Also, we suggest that cystatin C has a slightly better performance in this population. These results must be confirmed in larger cohorts, including CKD patients. 
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